Cargando…

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden

INTRODUCTION: The aim of the present study was to use real-world data from Swedish primary-care and national registries to understand clinical outcomes in patients with Type 2 diabetes (T2D) treated with liraglutide in clinical practice, and to compare with data from those treated with sitagliptin....

Descripción completa

Detalles Bibliográficos
Autores principales:	Lind, Marcus, Matsson, Per-Olov, Linder, Ragnar, Svenningsson, Irene, Jørgensen, Leif, Ploug, Uffe J., Gydesen, Helge, Dorkhan, Mozhgan, Larsen, Sara, Johansson, Gunnar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900983/ https://www.ncbi.nlm.nih.gov/pubmed/27216947 http://dx.doi.org/10.1007/s13300-016-0173-z

Ejemplares similares

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
por: Lorenzi, Maria, et al.
Publicado: (2016)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
por: Lind, Marcus, et al.
Publicado: (2015)

Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
por: Funch, Donnie, et al.
Publicado: (2019)

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2009)

Sitagliptin Successfully Ameliorates Glycemic Control in Werner Syndrome With Diabetes
por: Kitamoto, Takumi, et al.
Publicado: (2012)

Effects of sitagliptin beyond glycemic control: focus on quality of life
por: Sakamoto, Yoshiko, et al.
Publicado: (2013)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
por: Mezquita Raya, Pedro, et al.
Publicado: (2013)

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
por: Funch, D, et al.
Publicado: (2014)

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
por: Funch, Donnie, et al.
Publicado: (2021)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia
por: Mondragon, Angeles, et al.
Publicado: (2014)

Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
por: Li, Qian, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
por: Pérez, Antonio, et al.
Publicado: (2015)

Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients
por: Smits, Mark M., et al.
Publicado: (2016)

Systems approaches and their application: examples from Sweden
por: Olsson, Mats-Olov, et al.
Publicado: (2005)

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
por: Tajima, Naoko, et al.
Publicado: (2013)

Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
por: Li, Qian, et al.
Publicado: (2018)

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
por: Smits, Mark M., et al.
Publicado: (2016)

Treatment with pioglitazone induced significant, reversible mitral regurgitation
por: Dorkhan, Mozhgan, et al.
Publicado: (2008)

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes
por: Dencker, Magnus, et al.
Publicado: (2010)

The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss
por: Bell, David S.H.
Publicado: (2014)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Li, Mingxing, et al.
Publicado: (2017)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt
por: Elsisi, Gihan Hamdy, et al.
Publicado: (2022)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2019)

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)
por: Zenari, Luciano, et al.
Publicado: (2020)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Education, immigration and income as risk factors for hemoglobin A1c >70 mmol/mol when diagnosed with type 2 diabetes or latent autoimmune diabetes in adult: a population-based cohort study
por: Martinell, Mats, et al.
Publicado: (2017)

Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis
por: ODA, Hitomi, et al.
Publicado: (2014)

Incidence of venous thromboembolism in northern Sweden (VEINS): a population-based study
por: Johansson, Magdalena, et al.
Publicado: (2014)

Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study
por: Tomiyama, Hirofumi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mtivjqhgbv5p6tulmuhtodn7hp